My patient is on an intravenous nitroglycerin infusion for hypertensive emergency and has acute kidney injury precluding the use of angiotensin‑converting enzyme inhibitors (ACE inhibitors) or angiotensin II receptor blockers (ARBs); what oral medications can be used to transition them off the nitroglycerin drip?

Oral Antihypertensive Transition in AKI

For a patient on nitroglycerin drip with AKI precluding ACEi/ARB use, transition to oral calcium channel blockers (CCBs) as first-line, with beta-blockers as adjunctive therapy if tachycardia is present.

Primary Recommendation: Calcium Channel Blockers

The ESC Council on Hypertension guidelines 1 explicitly recommend CCBs for hypertensive emergencies, with nicardipine and clevidipine listed as effective IV agents that can be bridged to oral formulations. CCBs are safe in AKI and do not carry the hemodynamic risks to renal perfusion that ACEi/ARBs pose in this setting.

Specific CCB Options:

• Amlodipine (5-10 mg daily): Long-acting, once-daily dosing, predictable pharmacokinetics
• Nifedipine extended-release (30-90 mg daily): Avoid immediate-release formulations
• Diltiazem (120-360 mg daily): Non-dihydropyridine option if rate control also needed

Common pitfall: Avoid immediate-release nifedipine, which causes unpredictable hypotension and is explicitly discouraged for hypertensive crises 2.

Adjunctive Therapy: Beta-Blockers

The ESC guidelines 1 specifically state that "additional beta-blockade may be indicated for patients receiving nitroglycerine, especially if tachycardia is present." This addresses the reflex tachycardia commonly seen with nitrate therapy.

Beta-Blocker Options:

• Metoprolol (25-100 mg twice daily): Cardioselective, well-tolerated
• Labetalol (100-400 mg twice daily): Combined alpha/beta blockade, particularly useful if additional BP reduction needed
• Carvedilol (3.125-25 mg twice daily): Additional vasodilatory properties

Contraindications to avoid: Do not use beta-blockers if the patient has asthma, severe bradycardia, or heart block 1.

Alternative Agents

Loop Diuretics

If volume overload contributes to hypertension, the ESC guidelines 1 note that "concomitant administration of loop diuretics decreases volume overload and helps to further lower BP." Furosemide can be used even in AKI if the patient remains oliguric or volume-overloaded.

Clonidine

While listed in the ESC guidelines 1 as an IV option (onset 30 minutes, duration 4-6 hours), oral clonidine (0.1-0.2 mg every 8-12 hours) can be used but causes sedation and carries rebound hypertension risk if discontinued abruptly.

Critical Transition Strategy

Overlap the oral agents with the nitroglycerin drip before weaning:

1. Start oral CCB at therapeutic dose
2. Add beta-blocker if heart rate >80-90 bpm
3. Wait 2-4 hours for oral agents to reach therapeutic levels
4. Begin weaning nitroglycerin by 10-20 mcg/min decrements every 15-30 minutes
5. Monitor BP every 15 minutes during wean
6. Target mean arterial pressure reduction of no more than 25% in first 2-4 hours 3

Critical pitfall: Do not abruptly discontinue the nitroglycerin drip without established oral therapy, as this can cause rebound hypertension.

Why Not ACEi/ARBs in This Context

While recent research suggests nuanced benefits of ACEi/ARBs post-AKI 4, 5, these studies examined patients who had recovered from dialysis-requiring AKI. In acute AKI, ACEi/ARBs reduce glomerular filtration pressure and can worsen kidney function, particularly when multiple nephrotoxins are present 6. The ESC guidelines 1 list enalaprilat (IV ACEi) but note it's contraindicated in angioedema history and don't recommend it as first-line for most hypertensive emergencies.

Monitoring Requirements

• BP every 15 minutes during transition, then hourly for 6 hours
• Serum creatinine and potassium within 24-48 hours (CCBs don't typically worsen these, but monitor AKI progression)
• Heart rate monitoring if beta-blockers used
• Avoid target BP <140/90 mmHg acutely; gradual reduction over 24-48 hours is safer 3